C16 Biosciences vs Saluda Medical

Side-by-side comparison of AI visibility scores, market position, and capabilities

Saluda Medical leads in AI visibility (74 vs 36)
C16 Biosciences logo

C16 Biosciences

EmergingLife Sciences & BioTech

Sustainable Palm Oil Alternative via Fermentation

C16 Biosciences produces Palmless, a biofermentation-derived alternative to palm oil targeting the beauty, personal care, and food industries; raised $20M Series A led by Breakthrough Energy Ventures;

AI VisibilityBeta
Overall Score
D36
Category Rank
#106 of 198
AI Consensus
74%
Trend
stable
Per Platform
ChatGPT
41
Perplexity
32
Gemini
32

About

C16 Biosciences is a biotechnology company founded in 2017 by David Heller, Irina Gerry, and Harry McNamara and headquartered in New York City. The company developed a proprietary biomanufacturing platform that uses engineered yeast fermentation to produce Palmless — a sustainable, palm oil-equivalent ingredient designed for beauty, personal care, and food applications. Palm oil is one of the most widely used commodity oils in the world, but its production is responsible for massive tropical deforestation, habitat destruction, and biodiversity loss, particularly in Indonesia and Malaysia. C16's fermentation approach produces oils with the same functional performance as palm oil — high saturation, solid at room temperature, neutral flavor — without any agricultural land conversion.

Full profile
Saluda Medical logo

Saluda Medical

LeaderLife Sciences & BioTech

Neuromodulation & Spinal Cord Stimulation

Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.

AI VisibilityBeta
Overall Score
B74
Category Rank
#10 of 198
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
72
Perplexity
68
Gemini
80

About

Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.

Full profile

AI Visibility Head-to-Head

36
Overall Score
74
#106
Category Rank
#10
74
AI Consensus
73
stable
Trend
stable
41
ChatGPT
72
32
Perplexity
68
32
Gemini
80
30
Claude
71
33
Grok
71

Key Details

Category
Sustainable Palm Oil Alternative via Fermentation
Neuromodulation & Spinal Cord Stimulation
Tier
Emerging
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.